Nuvation Bio Revenue and Competitors
Estimated Revenue & Valuation
- Nuvation Bio's estimated annual revenue is currently $12.7M per year.
- Nuvation Bio's estimated revenue per employee is $230,236
- Nuvation Bio's total funding is $777M.
- Nuvation Bio's current valuation is $1.3B. (January 2022)
Employee Data
- Nuvation Bio has 55 Employees.
- Nuvation Bio grew their employee count by 22% last year.
Nuvation Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Nuvation Bio?
Nuvation Bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
keywords:N/A
$777M
Total Funding
55
Number of Employees
$12.7M
Revenue (est)
22%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
Nuvation Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director, Clinical Research | Reveal Email/Phone |
2 | VP, Head Data Science | Reveal Email/Phone |
3 | Accounting Operations Manager | Reveal Email/Phone |
4 | Facilities Manger | Reveal Email/Phone |
5 | Associate Director, Stock and 401k Administration | Reveal Email/Phone |
6 | Senior Director Analytical Development at Nuvation Bio | Reveal Email/Phone |
7 | Director | Reveal Email/Phone |
8 | Director, Corporate Development | Reveal Email/Phone |
9 | Director, Program Management | Reveal Email/Phone |
10 | VP Chemistry | Reveal Email/Phone |
Nuvation Bio News
Zero analysts have provided estimates for Nuvation Bio's earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate...
Overall market sentiment has been down on Nuvation Bio Inc (NUVB) stock lately. NUVB receives a Bearish rating from InvestorsObserver Stock...
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel...
NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the third quarter ended September 30, 2021 ...
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the second quarter ended June 30, 2021, an ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.2M | 55 | 31% | $18.9M |
#2 | $10.1M | 55 | 15% | N/A |
#3 | $5.9M | 55 | 12% | N/A |
#4 | $9.9M | 55 | -4% | N/A |
#5 | $11.2M | 55 | 6% | N/A |
Nuvation Bio Executives
| Name | Title |
|---|---|
| Stacy Markel | Chief People Officer |
| David Hanley | Chief Technical Operations Officer |
| Kerry Wentworth | Chief Regulatory Officer |
| David Liu | Chief Medical Officer |
| Sergey Yurasov | Chief Medical Officer |
| David Liu | Chief Medical Officer |
| David Hung | Founder, President and CEO |
| Jennifer Fox | Chief Financial Officer |
| Gary Hattersley | Chief Scientific Officer |
| Liang Fang | VP, Head of Data Science |
| Chris Miller | Vice President Chemistry |
| Anthony Golsorkhi | Vice President, Clinical Development |
| David Hung | Founder, President and CEO |
| Stephen Dang | Vice President, Legal |
| Lisa DeLuca | SVP, Regulatory Affairs |
| Melanie Morrison | SVP, Clinical Operations and Program Management |